



**Figure S1. Updated amino acid alignment of MCV with all known human polyomaviruses, SV40, LPyV and MPyV.** The three conserved domains CR1 (Conserved region 1), DnaJ or J domain and Rb binding motif are highlighted in colour. Region containing epitope site for CM2B4 is not conserved with other polyomaviruses. The alignment was done using ClustalW multiple alignment (Gonnet matrix), Macvector software.

**Supplementary Table S1. MCV Detection in MCC Samples**

Country	Total	MCV +ve	Method Used	Reference
USA	10	8 (80%)	PCR (LT and VP1) sequence analysis, Southern hybridization, and CM2B4 Staining	Feng et al, Science 2008 and Shuda et al., Int J Cancer 2009
USA	16	11 (68.7%)	qPCR (LT)	Garneski et al., J Invest Dermatology 2009
USA	13	7 (53.8%)	PCR (LT and VP1)	Ridd et al., J Invest Dermatology, 2009
USA	41	32 (78%)	PCR (LT and VP1)	Duncavage et al., Modern Pathology 2009
USA	53	42 (79.2%)	qPCR and CM2B4	Busam et al., Am J Surg Pathol 2009
USA	31	24 (77.4%)	qPCR (VP1)	Carter et al., J Nat Cancer Institute 2009
USA	22	13 (59.1%)	qPCR (LT)	Paulson et al., J Invest Dermatol 2009
USA	23	17 (73.9%)	PCR (Tag)	Bhatia et al., Int J Cancer 2010
USA	7	6 (85.7%)	qPCR (LT and VP1)	Loyo et al., Int J Cancer 2010
USA	6	4 (66.7%)	PCR (LT)	Lewis et al., Oral Surg, Oral Medicine, Oral Pathol, Oral Radiolo and Endodon 2010
USA	20	15 (75%)	CM2B4 Staining	Reisinger et al., J Am Acad Dermatol 2010
USA	4	2 (50%)	qPCR (LT)	Toracchio et al., Emerg Infect Diseases 2010
USA	80	59 (73.7%)	qPCR (LT)	Paulson et al., J Clin Oncol 2011
USA	4	4 (100%)	Hybrid capture and next-gen sequencing	Duncavage et al., J Molecular Diagnostics 2011
USA	51	47 (92.2%)	CM5E1 and CM2B4 Staining	Shuda et al., JCI 2011
USA	52	38 (73.1%)	qPCR (LT)	Lee et al., J Clin Virology 2011
USA	58	38 (65.5%)	PCR (LT)	Nardi et al., Clin Cancer Research 2012
Switzerland	30	20 (66.6%)	PCR (LT and VP1)	Mangana et al., Dermatology 2010
Spain	36	21 (58.3%)	CM2B4 staining	Shuda et al., Int J Cancer 2009
Netherlands	7	3 (42.8%)	PCR and sequence analysis (LT)	Wetzels et al., PLoS ONE, 2009
Korea	7	7 (100%)	PCR (LT)	Woo et al., J Plastic Reconstructive and Aesthetic Surg 2010
Korea	14	12 (85.7%)	qPCR (LT and VP1) and CM2B4 Staining	Jung et al., Histol Histopathol 2011
Japan	11	6 (54.5%)	PCR and qPCR (Tag and VP1)	Katano et al., J Medical Virology 2009
Japan	14	11 (78.6%)	PCR (LT)	Nakajima et al., J Dermatol Sci 2009
Japan	19	11 (57.8%)	qPCR (LT) and LT Ab Staining	Nakamura et al., Virology 2010
Japan	26	20 (76.9%)	qPCR (LT) and CM2B4 Staining	Kuwamoto et al., Human Pathology 2011

Italy	9	8 (88.8%)	PCR (LT and VP1)	Paolini et al., Virology Journal 2011
Italy	70	60 (85.7%)	PCR (LT)	Asioli et al., Modern Pathology 2011
Italy	18	18 (100%)	PCR (LT)	Biase et al., Human Pathology 2011
Hungary	8	7 (87.5%)	PCR (LT) and Sequence analysis	Varga et al., Br J Dermatol 2009
Australia	38	33 (86.8%)	qPCR (LT and VP1) and CM2B4 Staining	Schrama et al., J Invest Dermatol 2011
Germany	138	116 (84.1%)	qPCR (LT and VP1) and CM2B4 Staining	Schrama et al., J Invest Dermatol 2011
Germany	39	30 (76.9%)	PCR(LT and VP1) and sequence analysis	Kassem et al., Cancer Research 2008
Germany	53	45 (84.9%)	qPCR (LT)	Becker et al., J Invest Dermatology 2009
Germany	39	35(89.7%)	PCR (LT)	Wieland et al., Emerg Infect Dis 2009
Germany	98	90 (91.8%)	PCR (LT)	Helmbold et al., Mol Carcinogenesis 2009
Germany	33	21 (63.6%)	PCR (Tag) and Southern hybridization	Andres et al., J Cut Pathol 2010
Germany	50	43 (86%)	PCR (LT) and CM2B4 staining	Houben et al., Int J Cancer 2010
Germany	59	34 (57.6%)	PCR (LT and VP1)	Handschel et al., Int J Oral and Maxillofacial Surg 2010
Germany	52	43 (82.7%)	qPCR (LT and VP1)	Werling et al., Histopathology 2011
Germany	3	2 (66.7%)	Polyomavirus genotyping assay	Schmitt et al., Cancer Epid Biomarker and Prevention 2011
Germany	34	22 (64.7%)	PCR (Tag)	Andres et al., Acta Dermato-Venereologica 2011
Germany	43	37 (86%)	qPCR(LT)	Wieland et al., J Am Acad Dermatol 2011
Germany	142	111 (78.2%)	qPCR (LT and VP1)	Vlahova et al., Br J Dermatology 2012
France	9	8 (88.8%)	PCR (LT and VP1)	Foulogne et al., Emerg Infect Dis 2008
France	10	10 (100%)	PCR (Tag and VP1)	Sastre-Garau et al., J Pathology 2009
France	32	21 (65.6%)	PCR (LT and VP1)	Touze et al., Emerg Infec Diseases 2009
France	18	14 (77.8%)	qPCR (LT and VP1)	Foulogne et al., Br J Dermatol 2009
France	43	41 (95.3%)	qPCR (LT)	Laude et al., PLoS pathogens 2010
France	68	51 (75%)	qPCR (LT)	Touze et al., J Clin Oncol 2011
France	113	70 (61.9%)	PCR (LT) and qPCR (sT)	Martel-Jantin et al., Virology 2012
Finland	114	91 (79.8%)	qPCR(LT)and DNA sequencing	Sihto et al., J Natl Cancer Inst 2009
Finland	3	1 (33.3%)	qPCR (LT)	Koljonen et al., Nephrology Dialysis Transplantation 2009
Finland	5	5 (100%)	qPCR (LT)	Koljonen et al., Br J Cancer 2009
Finland	91	61 (67%)	qPCR (LT) and CM2B4 Staining	Sihto et al., Clin Cancer Research 2011

Finland	87	67 (77%)	qPCR(LT)	Waltari et al., Int J Cancer 2011
Canada	27	17 (62.9%)	CM2B4 Staining	Ly et al., Human Pathol 2011
Canada	30	29 (96.7%)	CM2B4 Staining	Erovic et al., Head and Neck 2012
Australia	21	5 (23.8%)	qPCR (LT)	Garneski et al., J Invest Dermatology 2009
Australia	104	19 (18.3%)	CM2B4 Staining	Palik et al., Human Pathology 2011
<b>Total</b>	<b>2354</b>	<b>=1743 (74.04%)</b>		